Compound: Palmitoylethanolamide
SMILES: O=C(NCCO)CCCCCCCCCCCCCCC
InChIKey: HXYVTAGFYLMHSO-UHFFFAOYSA-N
Synonyms: Palmitoylethanolamide, Palmidrol, 544-31-0, N-(2-Hydroxyethyl)hexadecanamide, Palmitoyl ethanolamide, Palmitic acid monoethanolamide, Hydroxyethylpalmitamide, Loramine P 256, palmitylethanolamide, Palmidrolum, Levagen, Palmdrol prodes, Anandamide (16:0), Monoethanolamine palmitic acid amide, palmitic monoethanolamide, Palmitinsaeure-beta-hydroxyethylamid, hexadecanoyl ethanolamide, N(2-hydroxyethyl)palmitide, 6R8T1UDM3V, N(2-hydroxyethyl) palmitide, NSC-23320, N-(2-hydroxyethyl)-palmitide, FSD-201, n-palmitoyl ethanolamide, AM 3112, CHEBI:71464, NSC23320, SCI-110 component palmitoylethanolamide, n-palmitoylethanolamide, N-(2-hydroxyethyl)palmitate, OptiPEA, RefChem:858399, 208-867-9, N-(2-Hydroxyethyl)palmitamide, Palmitamide MEA, Impulsin, N-palmitoylethanolamine, Palmitoyl-EA, HEXADECANAMIDE, N-(2-HYDROXYETHYL)-, Palmidrol [INN], C18H37NO2, MFCD00020562, N-hexadecanoylethanolamine, NSC 23320, PEA (Chemical), N-palmitoyl ethanolamine, N-hexadecanoyl-ethanolamine, DTXSID4042254, Palmidrol (INN), Palmitoylethanolamid?e, NCGC00015793-03, AM 3112;Loramine P 256;Mackpeart DR 14V, DTXCID2022254, Palmidrolum [INN-Latin], CAS-544-31-0, 2-Palmitoylaminoethanol, SR-01000076055, EINECS 208-867-9, UNII-6R8T1UDM3V, MimyX, Anandamide C16:0, Tocris-0879, Oleic Acid Impurity 2, N-hexadecyl-ethanolamine, PALMIDROL [MI], Lopac-P-0359, PALMIDROL [MART.], Palmityoletanolamide (PEA), 2-PALMITAMIDOETHANOL, PALMIDROL [WHO-DD], CBiol_002043, Lopac0_000905, BSPBio_001454, KBioGR_000174, KBioSS_000174, MLS002153421, SCHEMBL120518, BML2-B10, CHEMBL417675, GTPL3622, orb1300340, Palmidrol|N-palmitoylethanolamine, BDBM29083, KBio2_000174, KBio2_002742, KBio2_005310, KBio3_000347, KBio3_000348, Bio1_000329, Bio1_000818, Bio1_001307, Bio2_000174, Bio2_000654, HMS1361I16, HMS1791I16, HMS1989I16, HMS2234L19, HMS3264C10, HMS3266N08, HMS3374K03, HMS3402I16, HMS3411B14, HMS3649L03, HMS3675B14, N-(2-hydroxyethyl) hexadecanamide, Pharmakon1600-01506156, CS-D1253, NAE 16:0, Tox21_110222, ANA(16:0), EBC-47502, LMFA08040013, NAE(16:0), NSC760371, s4708, STL454872, AKOS002676363, Tox21_110222_1, CCG-204987, DB14043, FP76687, LP00905, NSC-760371, SDCCGSBI-0050880.P002, IDI1_033924, s10398, NCGC00015793-01, NCGC00015793-02, NCGC00015793-04, NCGC00015793-05, NCGC00015793-06, NCGC00015793-07, NCGC00015793-08, NCGC00015793-09, NCGC00015793-10, NCGC00015793-12, NCGC00024840-01, NCGC00024840-02, NCGC00024840-05, NCGC00024840-06, NCGC00024840-07, NCGC00024840-08, NCGC00024840-09, AS-14094, HY-20685, PALMITOYLETHANOLAMIDE [NFLIS-DRUG], SMR000058371, SY211643, Hexadecanoic acid (2-hydroxy-ethyl)-amide, EU-0100905, NS00013930, P2670, D08328, EN300-311967, P 0359, AB00918319_06, F530116, Q2159860, SR-01000076055-1, SR-01000076055-3, SR-01000076055-7, BRD-K68095457-001-04-4, BRD-K68095457-001-10-1, BRD-K68095457-001-11-9, Z2242151306, Hexadecanamide, N-(2-hydroxyethyl)-;N-(2-Hydroxyethyl)palmitamide;Palmitic acid monoethanolamide
Theoretical properties:
molecular_formula: C18H37NO2
molecular_weight: 299.5 g/mol
exact_mass: 299.282429423 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 16
heavy_atom_count: 21
topological_polar_surface_area: 49.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 98.5 °C
Descriptions:
pubchem: Palmitoyl ethanolamide is an N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid. It has a role as an anti-inflammatory drug, an anticonvulsant, an antihypertensive agent and a neuroprotective agent. It is a N-(long-chain-acyl)ethanolamine, an endocannabinoid and a N-(saturated fatty acyl)ethanolamine. It is functionally related to a hexadecanoic acid.
chebi: An <em>N</em>-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
chembl: PALMIDROL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, and lipid modulator.
A main target of PEA is proposed to be the peroxisome proliferator-activated receptor alpha (PPAR-α). PEA also has affinity to cannabinoid-like G-coupled receptors GPR55 and GPR119. PEA cannot strictly be considered a classic endocannabinoid because it lacks affinity for the cannabinoid receptors CB1 and CB2.